Application
IHC-P analysis of human breast carcinoma tissue using NFκB p65 (phospho Ser311) antibody in the absence (left) and presence (right) of blocking peptide.Application
WB analysis of extract from Hela cells untreated or treated with IFN using NFκB p65 antibody (Lane 1 and 2) and NFκB p65 (phospho Ser311) antibody (Lane 3 and 4).| Product Name | NFkB p65 (phospho Ser311) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit polyclonal antibody to NFkB-p65 (phospho S311)NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NFKB complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).[supplied by OMIM] |
| Modification | p-Ser311 |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | IHCIHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500-1:1000,IHC: 1:50-1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | MGC131774 NFKB3 |
|---|---|
| Target | NFkB-p65 (phospho S311) |
| Cellular Localization | Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction. |
Application
IHC-P analysis of human breast carcinoma tissue using NFκB p65 (phospho Ser311) antibody in the absence (left) and presence (right) of blocking peptide.
Application
WB analysis of extract from Hela cells untreated or treated with IFN using NFκB p65 antibody (Lane 1 and 2) and NFκB p65 (phospho Ser311) antibody (Lane 3 and 4).| Application Notes | Suggested starting dilutions are as follows. WB: 1:500-1:1000,IHC: 1:50-1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | PBS (without Mg2+and Ca2+), pH 7.4, 150mM NaCl, 0.02%sodium azide and 50% glycerol. |
